The European Commission, which controls one of the world's largest science budgets, has backed calls for free public access to taxpayer-funded research. Reed Elsevier is not thrilled.
"Taxpayers should not have to pay twice for scientific research and they need seamless access to raw data," said Neelie Kroes, European Commission vice-president for the Digital Agenda, though Kroes does not understand taxpayers are still paying twice. The largest open access publishers do tens of millions of dollars in revenue by shifting the cost from readers to scientists - who are taxpayer funded.
So it's a baby step, but a good one nonetheless. From 2014 all articles produced with funding from Horizon 2020 (($97.92 billion worth) will have to be accessible and the goal is for 60 percent of European publicly funded research to be available by 2016.
EU Commission backs open-access science publishing by Chris Wickham, Reuters
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Questions a Surface Pro 3 user has about Windows 10.
- Epigenetics Of Being Without Electricity For A Few Days
- Top Mass: CMS Again On Top!
- Multiple Sclerosis Patients Benefit From Exercise
- The Enemy Of Archaeology Is Not People, It's Salt
- Why Japan’s Deadly Ontake Eruption Could Not Be Predicted
- Mutational Robustness: Why Duplicate Genes Remain In The Genome
- "Lol, I don't have any problem with that...."
- "There is only one scientific understanding of the neuron-behavior linkage: Kandel et al spent 30..."
- "No wonder you have a problem comprehending climate change!..."
- "There are many truths of which the full meaning cannot be realized until personal experience has..."
- "Ha ha ha ROFL!..."
- Delayed introduction to gluten appears not to prevent celiac disease in at-risk infants
- Teen pregnancies, abortions plunge with free birth control
- B and T cell-targeting drug ameliorates chronic graft-versus-host disease in mice
- Clinical trial evaluates heterologous prime/boost regimens in preventative HIV vaccination
- Montmorency tart cherry juice lowered blood uric acid levels and a marker for inflammation